Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution.
|
患者入组仍然是全球药物研发中最关键的瓶颈之一，常常导致周期延误、成本攀升，并限制患者对创新疗法的可及性。在这一背景下，中国不仅凭借庞大的患者基数脱颖而出，更成为临床试验执行层面系统性创新的试验田。
|